] , “Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.”, Graefes Arch Clin Exp Ophthalmol, vol. 239, no. 7, pp. 1839-1851, 2021.
, “Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants with Hemiretinal Vein Occlusion Compared With Participants with Central Retinal Vein Occlusion (SCORE2) Report 18”, JAMA Ophthalmol, vol. 140, no. 5, pp. 458-464, 2022.
, “Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.”, JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
, “Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.”, Ophthalmology, vol. 118, no. 2, pp. 345-52, 2011.
, “Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial.”, JAMA Intern Med, vol. 174, no. 11, pp. 1736-45, 2014.
, “Change in Area of Intraretinal Macular Hemorrhages in Aflibercept- and Bevacizumab-treated Central Retinal and Hemiretinal Vein Occlusions: A SCORE2 Subanalysis”, in 43rd Annual Macula Society, San Diego, CA, 2020.
, “Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.”, JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
, “Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED).”, Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 417-25, 2011.
, “Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.”, JAMA, vol. 317, no. 20, pp. 2072-2087, 2017.
, “Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.”, Addiction, vol. 112, no. 6, pp. 1036-1044, 2017.
, “Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.”, JAMA Ophthalmol, vol. 133, no. 9, pp. 1022-9, 2015.
, “Influence of prior assignment on refusal rates in a trial of supplemental oxygen for retinopathy of prematurity.”, Paediatr Perinat Epidemiol, vol. 20, no. 4, pp. 348-59, 2006.
, “Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial”, JAMA Ophthalmol, vol. 139, no. 12, pp. 1285-1291, 2021.
, “Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.”, JAMA Ophthalmol, vol. 137, no. 3, pp. 281-287, 2019.
, “Month 60 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion”, Am J Ophthalmol, vol. 240, pp. 330-341, 2022.
, “A new protocol for evaluating putative causes for multiple variables in a spatial setting, illustrated by its application to European cancer rates.”, Am J Hum Biol, vol. 16, no. 1, pp. 1-16, 2004.
, “Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial.”, JAMA Ophthalmol, 2019.
, “Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.”, Am J Drug Alcohol Abuse, vol. 37, no. 5, pp. 350-7, 2011.
, “A pulmonary score for assessing the severity of neonatal chronic lung disease.”, Pediatrics, vol. 115, no. 4, pp. e450-7, 2005.
, “A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlus”, Arch Ophthalmol, vol. 127, no. 9, pp. 1101-14, 2009.
, “SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.”, Ophthalmology, vol. 116, no. 3, pp. 504-12, 2009.
, “SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.”, Ophthalmology, vol. 118, no. 7, pp. 1364-72, 2011.
, “SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.”, Ophthalmology, vol. 116, no. 4, pp. 756-61, 2009.
, “SCORE Study report 3: study design and baseline characteristics.”, Ophthalmology, vol. 116, no. 9, pp. 1770-1777.e1, 2009.